AB Science Updates on Masitinib's ALS Marketing Application
AB Science SA (Euronext - FR0010557264 - AB) recently announced crucial updates concerning its application for conditional marketing authorization of masitinib, a promising treatment for amyotrophic lateral sclerosis (ALS). The announcement comes after the European Medicines Agency (EMA) confirmed a negative opinion regarding the conditional marketing authorization following a Committee for Medicinal Products for Human Use (CHMP) meeting. Despite challenges, the company had requested a re-examination considering the pressing need for ALS patients to access potential cutting-edge treatments.
A Closer Look at Masitinib's Study Results
Masitinib's clinical trial, referred to as AB10015, demonstrated encouraging results in relation to overall survival rates for ALS patients. In the primary analysis of normal progressors, patients experienced an increase in median survival of +6 months. This result is particularly notable in a specific subgroup of patients who had not yet suffered a complete loss of function—indicating a +12 months benefit in survival, thereby underscoring masitinib's potential.
Scientific Advisory Group's Important Contribution
A Scientific Advisory Group - Neurology (SAG-N) was convened for this re-examination, with experts supporting the classification of Fast and Normal progressors and affirming the methodology used in the study. Their insights not only validate AB Science's approach but also strengthen the design for the upcoming confirmatory study of masitinib in the ALS population.
Health Canada’s Position and Future Steps
In separate news, AB Science faced a decision regarding its submission to Health Canada. Although new data was presented, the organization concluded that it could not utilize this data within the re-examination process, leading to their decision to not pursue the reconsideration of its application. Instead, Health Canada has suggested that the company could submit a brand-new application to address these concerns.
CEO Insights on Patient Commitment
AB Science's CEO, Alain Moussy, expressed gratitude towards patients and physicians who contributed to the re-examination process. Highlighting the commitment to patient care reiterates the company's dedication to advancing masitinib—a drug that has shown potential in extending survival for patients benefitting from compassionate use. Moussy emphasized that the company’s primary focus is now on progressing towards the phase 3 confirmatory studies necessary for achieving full approval.
About AB Science and Its Mission
Established in 2001, AB Science focuses on developing protein kinase inhibitors, targeting significant medical needs and rare diseases. Their innovative portfolio includes masitinib, which has already gained approval in veterinary medicine and is currently under development for various human health applications including oncology, neurological disorders, and beyond. AB Science is headquartered in Paris and continues to work diligently towards solutions for life-threatening conditions.
Frequently Asked Questions
What is the latest update regarding AB Science and masitinib?
AB Science has announced the EMA's negative opinion on the conditional marketing authorization of masitinib for ALS but remains committed to progressing through re-examination procedures.
How does masitinib aim to help ALS patients?
The clinical data from masitinib's trials show promising survival benefits, indicating it could lead to extended survival for ALS patients, particularly when used at early stages.
What were the findings from the AB10015 study?
The study showed an increase in median overall survival of +6 months for normal progressors and a significant +12 months for a specific subgroup of patients who had not lost full function.
What was the role of Health Canada in this process?
Health Canada informed AB Science that presented data would be viewed as new and not part of a reconsideration, allowing the company to consider submitting a new application instead.
What is AB Science's primary focus moving forward?
The primary focus is on advancing the phase 3 confirmatory studies of masitinib in ALS to achieve full marketing authorization.
